Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Carboplatin with Methotrexate/BBBD in PCNSL
NCT00293475Phase 2Unknown
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Oct 2005
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in primary central nervous system lymphoma (PCNSL), sponsored by OHSU Knight Cancer Institute. Status: unknown.
02
Drugs
rituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00293475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293475.